Ignite Creation Date:
2025-12-25 @ 1:38 AM
Ignite Modification Date:
2025-12-25 @ 11:54 PM
Study NCT ID:
NCT06821594
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2025-02-12
First Post:
2025-02-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.
Sponsor:
Jinnah Postgraduate Medical Centre
Organization:
Study Overview
Official Title:
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.
Detailed Description:
Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: